PRID

Main information

  • Trade name:
  • PRID DELTA 1.55 g vaginal delivery system
  • Pharmaceutical form:
  • Vaginal device
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • PRID DELTA 1.55 g vaginal delivery system
    Ireland
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • progesterone
  • Therapeutic area:
  • Cattle

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • FR/V/0215/001
  • Authorization date:
  • 13-02-2012
  • EU code:
  • FR/V/0215/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

1/5 Dokument1

ANNEXI

SUMMARYOFPRODUCTCHARACTERISTICS

2/5 Dokument1

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Syncrostim500IUlyophilisateandsolventforsolutionforinjectionforcattleandsheep

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Lyophilisatevialscontains:

Activesubstance:

EquineserumGonadotrophin(eCG,formerlyknownasPMSG)...............500IU

Solventvialcontains:

Benzylalcohol.......................................................................................16.5mg/ml

Reconstitutedsolutionfor1doseof2mlcontains:

Activesubstances

EquineserumGonadotrophin(eCG,formerlyknownasPMSG) 500IU

Excipients

Benzylalcohol 33.0mg

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Lyophilisateandsolventforsolutionforinjection

Lyophilisate:freeze-driedproductintheformofpowderagglomeratedincotton-likepellets.

Solvent:clearcolourlesssolution.

Reconstitutedsolution:clearcolourlesssolution.

4. CLINICALPARTICULARS

4.1 Targetspecies

Cattle,Sheep.

4.2 Indicationsforuse,specifyingthetargetspecies

Innoncyclingcattle(cowsandheifers)andinewesandewe-lambs:

Inductionandsynchronizationofoestrusandovulation.Tobeusedincombinationwithaprogestagen.

4.3 Contraindications

Seesection4.7.

4.4 Specialwarningsforeachtargetspecies

None.

4.5 Specialprecautionsforuse

Specialprecautionsforuseinanimals

3/5 Dokument1

Incaseofanaphylacticshock,symptomatic treatment(e.g.adrenalineorcorticosteroids)shouldbe

administered.

Specialprecautionstobetakenbythepersonadministeringtheveterinarymedicinal

producttoanimals

Careshouldbetakenwhenhandlingtheproducttoavoidself-injection.Incaseofaccidentalself-

injection,seekmedicaladvice,andshowthepackageleaflet.

Washhandsafterhandlingtheproduct.

StudiesinlaboratoryanimalsexhibitedteratogeniceffectsaftertheadministrationofeCG.Pregnant

women,thoseintendingtobecomepregnant,orwhosepregnancystatusisunknown,shouldnotusethe

product.

Accidentalspillageontheskinshouldbewashedoffimmediatelywithsoapandwater.

4.6 Adversereactions(frequencyandseriousness)

eCGisanexogenousproteinforspeciesotherthanequine.Therefore,antigen-antibodyreactionsmay

result.Inveryrarecases,repeatedadministrationsofeCGcanprovokeanaphylacticshock(see

section4.5).

4.7 Useduringpregnancy,lactationorlay

StudiesinlaboratoryanimalshaveshownteratogeniceffectsafteradministrationofeCG.

Thesafetyoftheveterinarymedicinalproducthasnotbeenestablishedduringpregnancyandlactation.

Donotuseduringpregnancy

4.8 Interactionwithothermedicinalproductsandotherformsofinteraction

Noneknown.

4.9 Amountstobeadministeredandadministrationroute

Intramuscularuse.

500IUofEquineserumgonadotrophin(eCG)peranimalinoneadministrationcorrespondingto2mlof

thereconstitutedsolution.

Dissolvethelyophilisatewith2mlofsolvent.Mixuntilcompletelydissolvedtoobtainahomogenous

solution.

Thereconstitutedsolutionshouldbeusedimmediately.

Theproductshouldbeadministeredatthetimeoftheprogestagendevicewithdrawal.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Administrationofhigherdosesthanrecommendeddosesmayincreasetheriskoftwinsincattleand

tripletsinsheep.

4.11Withdrawalperiod(s)

Meatandoffal:zerodays

Milk:zerodays

4/5 Dokument1

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:gonadotropins

ATCvetcode:QG03GA03

5.1 Pharmacodynamicproperties

EquineSerumGonadotrophin(eCG,inthepastcalledPMSG)isalargeglycoproteinsecretedduring

pregnancyinthemareanditsstructureissimilartotheendogenousgonadotrophinhormones:FSHand

LH.

eCGexertsitseffectsonFSHandLHreceptorsoftargetcellsdistributedinthegonads:infemales,

eCGsupportstheovarianfollicularmaturationbystimulatingthegrowthanddevelopmentofantral

follicles.Inovineandinnon-cyclingbovinefemale,itsuseisrecommendedafteratreatmentforthe

synchronizationofœstruswithaprogestagen:eCGimprovesfolliclematurationandovulationrateand

allowssynchronizationofovulation.

5.2 Pharmacokineticparticulars

Inplasma,eCGdeclinesbiphasicallywithspeciesterminalhalf-livesof22-64hoursand118-220hours

asmeasuredinsheep(i.v.,i.m.)andcows(i.v.,i.m.)respectively.

eCGismainlydegradedinliverandkidneyandeliminatedintheurine.

6. PHARMACEUTICALPARTICULARS

6.1 Listofexcipients

Lyophilisate:Mannitol.

Solvent:

Benzylalcohol.

Sodiumchloride.

Waterforinjections.

6.2 Incompatibilities

Intheabsenceofcompatibilitystudies,thisveterinarymedicinalproductmustnotbemixedwithother

veterinarymedicinalproducts.

6.3 Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:30months

Solvent:shelf-lifeafterfirstopeningthevial:28days.

Shelflifeafterreconstitutionaccordingtodirections:useimmediately.

6.4.Specialprecautionsforstorage

Lyophilisate:protectfromlight.

Storeinarefrigerator(2

C-8

C)

5/5 Dokument1

6.5 Natureandcompositionofimmediatepackaging

Primarypackaging:

Lyophilisate:

ColourlessglassvialtypeIclosedwithachlorobutylstopperandaluminiumcapsule.

Solvent:

ColourlessglassvialtypeIIclosedwithachlorobutylstopperandaluminiumcapsule.

Packsizes:

Cardboardboxcontaining5vialsoflyophilisateandonevialof10mlsolvent

Cardboardboxcontaining10vialsoflyophilisateand2vialsof10mlsolvent

Cardboardboxcontaining25vialsoflyophilisateandonevialof50mlsolvent

Notallpacksizesmaybemarketed.

6.6 Specialprecautionsforthedisposalofunusedveterinarymedicinalproductorwaste

materialsderivedfromtheuseofsuchproducts

Anyunusedproductorwastematerialsshouldbedisposedofinaccordancewithnationalrequirements.

7. MARKETINGAUTHORISATIONHOLDER

8. MARKETINGAUTHORISATIONNUMBER(S)

9. DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

10 DATEOFREVISIONOFTHETEXT

PROHIBITIONOFSALE,SUPPLYAND/ORUSE

29-11-2018

FDA approves first treatment for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder

FDA approves first treatment for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder

FDA approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a rare autoimmune disorder. This is the first FDA approval of a treatment for LEMS.

FDA - U.S. Food and Drug Administration

27-11-2018

Sunshine Mills, Inc. Issues Voluntary Recall of Dry Dog Food Due to Potentially Elevated Levels of Vitamin D

Sunshine Mills, Inc. Issues Voluntary Recall of Dry Dog Food Due to Potentially Elevated Levels of Vitamin D

Sunshine Mills, Inc. is issuing a voluntary recall of select products of Evolve Puppy, Sportsman’s Pride Large Breed Puppy and Triumph Chicken and Rice Dog Food (reference below) due to potentially elevated levels of Vitamin D.

FDA - U.S. Food and Drug Administration

28-6-2018

Minister Bruno Bruins verbetert transparantie zorgverzekeringen

Minister Bruno Bruins verbetert transparantie zorgverzekeringen

Er zijn in Nederland 55 verschillende standaard basisverzekeringen. In de praktijk worden verzekeringen onder allerlei namen en in verschillende verpakkingen aangeboden. Een van de verpakkingsvormen zijn de ongeveer 51.000 verschillende collectieve zorgverzekeringen. Hierdoor is de zorgverzekeringsmarkt ondoorzichtig geworden en is goed vergelijken een haast onmogelijke opgave. Minister Bruno Bruins (Medische Zorg) wil daarom dat zorgverzekeraars zorgen voor meer transparantie, onder andere door precies ...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

6-5-2014

Guidance material to doctors and users of contraceptive pills

Guidance material to doctors and users of contraceptive pills

The EU Pharmacovigilance Risk Assessment Committee (PRAC) recently completed a review of the risk of blood clots (VTE) with contraceptive pills and other combined hormonal contraceptives. Combined hormonal contraceptives contain two types of hormone, oestrogen and progesterone, and are available as pills, transdermal patches and vaginal rings.

Danish Medicines Agency

6-8-2018

Fampyra (Biogen Netherlands B.V.)

Fampyra (Biogen Netherlands B.V.)

Fampyra (Active substance: fampridine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5385 of Mon, 06 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2097/T/43

Europe -DG Health and Food Safety

17-7-2018

Firdapse (BioMarin Europe Ltd)

Firdapse (BioMarin Europe Ltd)

Firdapse (Active substance: amifampridine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4779 of Tue, 17 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1032/T/57

Europe -DG Health and Food Safety

4-6-2018

Yervoy (Bristol-Myers Squibb Pharma EEIG)

Yervoy (Bristol-Myers Squibb Pharma EEIG)

Yervoy (Active substance: ipilimumab) - Centralised - 2-Monthly update - Commission Decision (2018)3618 of Mon, 04 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2213/II/55

Europe -DG Health and Food Safety

28-5-2018

Seresto and its associated name Foresto

Seresto and its associated name Foresto

Seresto and its associated name Foresto (Active substance: imidacloprid/flumethrin) - Community Referrals - Art 13 - Commission Decision (2018)3404 of Mon, 28 May 2018 European Medicines Agency (EMA) procedure number: EMEA/V/A/125

Europe -DG Health and Food Safety